Q32 Bio shareholders back directors and pay plan
Rhea-AI Filing Summary
Q32 Bio Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders representing 11,833,800 common shares out of 15,629,463 entitled shares, or 75.71% of outstanding shares as of April 15, 2026, were present in person or by proxy.
All three Class II director nominees – Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. – were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, stockholders approved, on a non-binding, advisory basis, the compensation of the company’s named executive officers. The report was signed on behalf of the company by Chief Executive Officer Jodie Morrison.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented: 11,833,800 shares
Shares entitled to vote: 15,629,463 shares
Meeting participation: 75.71%
+3 more
6 metrics
Shares represented
11,833,800 shares
Common stock represented at 2026 Annual Meeting
Shares entitled to vote
15,629,463 shares
Common stock entitled to vote as of April 15, 2026
Meeting participation
75.71%
Percentage of outstanding common stock represented at the meeting
Auditor ratification support
11,821,046 votes for
Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026
Say-on-pay support
8,072,067 votes for
Non-binding advisory vote on named executive officer compensation
Director vote – Jodie Morrison
8,591,626 votes for
Election as Class II director
Key Terms
emerging growth company, broker non-votes, independent registered public accounting firm, non-binding, advisory vote, +1 more
5 terms
emerging growth company regulatory
"Emerging growth company During the 2026 Annual Meeting of Stockholders"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
broker non-votes financial
"Votes For | | Votes Against | | Abstentions | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding, advisory vote financial
"Non-Binding, Advisory Vote on the Compensation of the Company’s Named Executive Officers"
Class II directors financial
"The stockholders of the Company elected Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D., as Class II directors"
FAQ
What did Q32 Bio Inc. (QTTB) stockholders vote on at the 2026 Annual Meeting?
Stockholders voted on electing three Class II directors, ratifying Ernst & Young LLP as independent auditor for 2026, and approving, on a non-binding advisory basis, the compensation of named executive officers. All three proposals received sufficient support to pass.
Were all Q32 Bio Inc. (QTTB) Class II director nominees elected in 2026?
Yes. Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D., were each elected as Class II directors for three-year terms ending at the 2029 annual meeting, continuing until a successor is elected and qualified or earlier death, resignation, or removal.
Did Q32 Bio (QTTB) stockholders approve the auditor for fiscal year 2026?
Yes. Stockholders ratified the appointment of Ernst & Young LLP as Q32 Bio Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 11,821,046 votes for, 7,909 votes against, and 4,845 abstentions recorded.
How did Q32 Bio (QTTB) stockholders vote on executive compensation in 2026?
Stockholders approved, on a non-binding, advisory basis, the compensation of Q32 Bio’s named executive officers. The vote totals were 8,072,067 shares for, 400,598 shares against, and 143,389 abstentions, with 3,217,746 broker non-votes recorded on this proposal.
AI-generated analysis. How Rhea-AI works. Not financial advice.
